S&P Futures
4,381.50 -93.25 (-2.08%) Dow Futures
33,992.00 -261.00 (-0.76%) Nasdaq Futures
14,308.00 -193.00 (-1.33%) Russell 2000 Futures
2,008.40 -23.30 (-1.15%) Crude Oil
undefined (0) Gold
1,841.10 -0.60 (-0.03%)
Adaptimmune Therapeutics plc (ADAP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.8900 |
| Open | 2.8100 |
| Bid | 2.8800 x 2200 |
| Ask | 2.9200 x 1000 |
| Day's Range | 2.6800 - 2.9500 |
| 52 Week Range | 2.6800 - 7.3400 |
| Volume | |
| Avg. Volume | 876,018 |
| Market Cap | 457.678M |
| Beta (5Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0020 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.17 |
- Motley Fool
2 Cancer Stocks With Absurdly Low Valuations
The potential for four or more interest rate hikes by the Federal Reserve over the course of 2022 has been weighing heavily on growth stocks of late. Investors are clearly pivoting toward safe havens like value and dividend stocks ahead of this perceived eventuality. Shares of the cancer specialists Adaptimmune Therapeutics (NASDAQ: ADAP) and Clovis Oncology (NASDAQ: CLVS) are both trading at absurdly low valuations following their steep downturns over the past several weeks.
- Zacks
4 Biotechs That Could Be Potential Takeover Targets in 2022
We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.
- Motley Fool
Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November
A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.
